MACS® Immuno-Oncology Days
MACS Dendritic Cells Day in Barcelona
Agenda
| 09:00 a.m. | Registration |
| 09:30 a.m. | Introduction Daniel Benitez-Ribas Dept. of Immunology, Hospital Clinic de Barcelona, IDIBAPS, Spain |
| 09:45 a.m. | Redefining bovine and porcine in vitro models of antigen presenting cells Maria Montoya Centro de Investigaciones Biológicas, CIB-CSIC, Madrid, Spain |
| 10:15 a.m. | TH1 priming by vaccine dendritic cells depends on IL-12 production by endogenous migratory XCR1+ dendritic cells Manfred Lutz Institute for Virology and Immunobiology, Julius-Maximilian University of Würzburg, Germany |
| 10:45 a.m. | Autologous tolerogenic dendritic cells for rheumatoid arthritis: the AuToDeCRA study Catharien Hilkens Institute of Cellular Medicine, Newcastle University, UK |
| 11:15 a.m. | Tumor-derived dendritic cells to slow down tumor growth Damya Laoui Vrije Universiteit Brussel, VIB, Belgium |
| 11:45 a.m. | Coffee break |
| 12:15 p.m. | Human pDCs orchestrate the attraction of cytolytic immune effector cells in melanoma DC-vaccination Georgina Flórez Dept. of Tumor Immunology, Radboud Institute for Molecular Life Sciences, Nijmegen, Netherlands |
| 12:45 p.m. | Update on monocyte-derived dendritic cell vaccinations to treat leukemia and solid tumors Evelien Smits Center for Cell Therapy and Regenerative Medicine, Antwerp University Hospital, Belgium |
| 01:15 p.m. | Personalized whole tumor antigen vaccines in ovarian cancer: using tumors for therapy Lana Kandalaft Center of Experimental Therapeutics, Ludwig Institute for Cancer Research, Lausanne, Switzerland |
| 01:45 p.m. | Discussion |
| 02:00 p.m. | Refreshments and networking |
Copyright © 2023 Miltenyi Biotec and/or its affiliates. All rights reserved.
